@phdthesis{Lanz2022,
  author    = {Lanz, Meike Berit},
  title     = {Lebensqualit{\"a}t und Bed{\"u}rfnisse von Patientinnen mit metastasiertem Brustkrebs - Eine Erhebung im Rahmen der Pilotphase des BRE-4-MED-Projektes},
  doi       = {10.25972/OPUS-29684},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-296847},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2022},
  abstract  = {Die Ziele dieser Arbeit waren, das aktuelle Informationsbed{\"u}rfnis von metastasierten Brustkrebspatientinnen und -patienten, deren Einsch{\"a}tzung der Arzt-Patient-Kommunikation sowie erwiesene Pr{\"a}diktoren der QoL zu erheben und auf einen Zusammenhang mit der aktuellen patientenseitigen QoL zu untersuchen. Zu dieser oder {\"a}hnlichen Fragestellungen existieren lediglich Publikationen mit Brustkrebspatientinnen ohne Metastasierung. Studien mit ausschließlich metastasierten Brustkrebs-patientinnen sind generell sehr selten. Die Daten von 30 Patientinnen und einem Patienten mit metastasiertem Brustkrebs, rekrutiert in vier Kliniken in Bayern und Baden-W{\"u}rttemberg im Rahmen der Pilotphase des BRE-4-MED-Projektes, konnten ausgewertet werden. Die Studienteilnehmer waren zum Zeitpunkt der Rekrutierung zwischen 30 und 85 Jahre alt, das Durchschnittsalter betrug 57 Jahre (SD = 13,4). F{\"u}r die Datenerhebung wurden nebst einzelner ordinalskalierter Fragen standardisierte, teils modifizierte Frageb{\"o}gen wie die CARE-Skala, PROMIS PF4a, PHQ-4 oder ein Item des EORTC QLQ-C30 verwendet. In der QoL-Messung durch ein Item des EORTC QLQ-C30 Fragebogens erzielten die Probandinnen und Probanden geringf{\"u}gig schlechtere Werte als eine gesunde deutsche Vergleichspopulation. Angesichts bisheriger Forschungsergebnisse wurde mit unbefriedigten Informations- und Kommunikationsbed{\"u}rfnissen gerechnet. Außerdem wurden Zusammenh{\"a}nge zwischen der QoL und unbefriedigten Informationsbed{\"u}rfnissen, einer schlechten Arzt-Patient-Kommunikation sowie Pr{\"a}diktoren der QoL erwartet. Diese Hypothesen wurden durch die vorliegende Arbeit zum Teil best{\"a}tigt, n{\"a}mlich das Vorliegen von unerf{\"u}llten Informationsbed{\"u}rfnissen sowie einer Korrelation der QoL mit Depression, k{\"o}rperlicher Funktionalit{\"a}t und mit Schmerz. Ein Zusammenhang mit dem Alter der Befragten bestand, jedoch genau entgegengesetzt der Erwartung. Letzteres Ergebnis sowie die nicht signifikanten Ergebnisse der Studie sind am ehesten durch eine zu geringe Probandenzahl bedingt. In puncto Informationsbed{\"u}rfnisse der Patienten sowie Pr{\"a}diktoren der QoL konnte die vorliegende Arbeit die bisherige Forschung gr{\"o}ßtenteils best{\"a}tigen, woraus die {\"a}rztlichen Handlungsempfehlungen abgeleitet werden k{\"o}nnen, auf diese Themen im Umgang mit metastasierten Mammakarzinompatienten besonders einzugehen. Die Aussagekraft der vorliegenden Ergebnisse ist allerdings angesichts der bisherigen Stichprobengr{\"o}ße als gering einzustufen, die Wiederholung der durchgef{\"u}hrten Analysen in der Hauptphase des BRE-4-MED-Projektes w{\"a}ren w{\"u}nschenswert. Das BRE-4-MED-Register ist zusammenfassend als vielversprechendes Projekt zur Erg{\"a}nzung der Versorgungsforschung und langfristig zur Verbesserung der Versorgung metastasierter Brustkrebspatienten einzustufen.},
  subject      = {Lebensqualit{\"a}t},
  language  = {de}
}
@article{KaemmererKlementJoosetal.2021,
  author    = {K{\"a}mmerer, Ulrike and Klement, Rainer J. and Joos, Fabian T. and S{\"u}tterlin, Marc and Reuss-Borst, Monika},
  title     = {Low carb and ketogenic diets increase quality of life, physical performance, body composition, and metabolic health of women with breast cancer},
  series = {Nutrients},
  volume    = {13},
  journal   = {Nutrients},
  number    = {3},
  issn      = {2072-6643},
  doi       = {10.3390/nu13031029},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-234209},
  year      = {2021},
  abstract  = {Breast cancer (BC) patients often ask for a healthy diet. Here, we investigated a healthy standard diet (SD), a low carb diet (LCD), and a ketogenic diet (KD) for BC patients during the rehabilitation phase. KOLIBRI was an open-label non-randomized one-site nutritional intervention trial, combining inpatient and outpatient phases for 20 weeks. Female BC patients (n = 152; mean age 51.7 years) could select their diet. Data collected were: Quality of life (QoL), spiroergometry, body composition, and blood parameters. In total 30, 92, and 30 patients started the KD, LCD, and SD, respectively. Of those, 20, 76, and 25 completed the final examination. Patients rated all diets as feasible in daily life. All groups enhanced QoL, body composition, and physical performance. LCD participants showed the most impressive improvement in QoL aspects. KD participants finished with a very good physical performance and muscle/fat ratio. Despite increased cholesterol levels, KD patients had the best triglyceride/high-density lipoprotein (HDL) ratio and homeostatic model assessment of insulin resistance index (HOMA-IR). Most metabolic parameters significantly improved in the LCD group. SD participants ended with remarkably low cholesterol levels but did not improve triglyceride/HDL or HOMA-IR. In conclusion, both well-defined KDs and LCDs are safe and beneficial for BC patients and can be recommended during the rehabilitation phase.},
  language  = {en}
}
@article{WischnewskySchwentnerDiessneretal.2021,
  author    = {Wischnewsky, Manfred and Schwentner, Lukas and Diessner, Joachim and De Gregorio, Amelie and Joukhadar, Ralf and Davut, Dayan and Salmen, Jessica and Bekes, Inga and Kiesel, Matthias and M{\"u}ller-Reiter, Max and Blettner, Maria and Wolters, Regine and Janni, Wolfgang and Kreienberg, Rolf and W{\"o}ckel, Achim and Ebner, Florian},
  title     = {BRENDA-Score, a hghly significant, internally and externally validated prognostic marker for metastatic recurrence: analysis of 10,449 primary breast cancer patients},
  series = {Cancers},
  volume    = {13},
  journal   = {Cancers},
  number    = {13},
  issn      = {2072-6694},
  doi       = {10.3390/cancers13133121},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-241064},
  year      = {2021},
  abstract  = {Background Current research in breast cancer focuses on individualization of local and systemic therapies with adequate escalation or de-escalation strategies. As a result, about two-thirds of breast cancer patients can be cured, but up to one-third eventually develop metastatic disease, which is considered incurable with currently available treatment options. This underscores the importance to develop a metastatic recurrence score to escalate or de-escalate treatment strategies. Patients and methods Data from 10,499 patients were available from 17 clinical cancer registries (BRENDA-project. In total, 8566 were used to develop the BRENDA-Index. This index was calculated from the regression coefficients of a Cox regression model for metastasis-free survival (MFS). Based on this index, patients were categorized into very high, high, intermediate, low, and very low risk groups forming the BRENDA-Score. Bootstrapping was used for internal validation and an independent dataset of 1883 patients for external validation. The predictive accuracy was checked by Harrell's c-index. In addition, the BRENDA-Score was analyzed as a marker for overall survival (OS) and compared to the Nottingham prognostic score (NPS). Results: Intrinsic subtypes, tumour size, grading, and nodal status were identified as statistically significant prognostic factors in the multivariate analysis. The five prognostic groups of the BRENDA-Score showed highly significant (p < 0.001) differences regarding MFS:low risk: hazard ratio (HR) = 2.4, 95\%CI (1.7-3.3); intermediate risk: HR = 5.0, 95\%CI.(3.6-6.9); high risk: HR = 10.3, 95\%CI (7.4-14.3) and very high risk: HR = 18.1, 95\%CI (13.2-24.9). The external validation showed congruent results. A multivariate Cox regression model for OS with BRENDA-Score and NPS as covariates showed that of these two scores only the BRENDA-Score is significant (BRENDA-Score p < 0.001; NPS p = 0.447). Therefore, the BRENDA-Score is also a good prognostic marker for OS. Conclusion: The BRENDA-Score is an internally and externally validated robust predictive tool for metastatic recurrence in breast cancer patients. It is based on routine parameters easily accessible in daily clinical care. In addition, the BRENDA-Score is a good prognostic marker for overall survival. Highlights: The BRENDA-Score is a highly significant predictive tool for metastatic recurrence of breast cancer patients. The BRENDA-Score is stable for at least the first five years after primary diagnosis, i.e., the sensitivities and specificities of this predicting system is rather similar to the NPI with AUCs between 0.76 and 0.81 the BRENDA-Score is a good prognostic marker for overall survival.},
  language  = {en}
}
@article{SitterSchlesingerReinholdetal.2022,
  author    = {Sitter, Magdalena and Schlesinger, Tobias and Reinhold, Ann-Kristin and Scholler, Axel and Heymann, Christian von and Welfle, Sabine and Bartmann, Catharina and W{\"o}ckel, Achim and Kleinschmidt, Stefan and Schneider, Sven and Gottschalk, Andr{\´e} and Greve, Susanne and Wermelt, Julius Z. and Wiener, Roland and Schulz, Frank and Chappell, Daniel and Brunner, Maya and Neumann, Claudia and Meybohm, Patrick and Kranke, Peter},
  title     = {COVID-19 in der geburtshilflichen An{\"a}sthesie: Prospektive Erfassung von SARS-CoV-2-Infektionen zum Zeitpunkt der Geburt sowie des peripartalen Verlaufs SARS-CoV-2-positiver Schwangerer},
  series = {Der Anaesthesist},
  volume    = {71},
  journal   = {Der Anaesthesist},
  number    = {6},
  issn      = {1432-055X},
  doi       = {10.1007/s00101-021-01068-6},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-264878},
  pages     = {452-461},
  year      = {2022},
  abstract  = {Hintergrund Im Rahmen der Pandemie des SARS-CoV-2-Virus erlangte das Patientenkollektiv der Schwangeren fr{\"u}h Aufmerksamkeit. Initial wurde angesichts sich fr{\"u}h abzeichnender Krankheitsf{\"a}lle bei j{\"u}ngeren Patienten mit einem erheblichen Aufkommen peripartal zu betreuender, COVID-19-positiver Schwangerer gerechnet. Ziel der Arbeit Diese Arbeit vermittelt einen Einblick in die SARS-CoV-2-Infektionszahlen im Rahmen der geburtshilflichen An{\"a}sthesie zu Beginn der Pandemie sowie w{\"a}hrend der zweiten Infektionswelle in Deutschland. Methoden {\"U}ber das COALA-Register (COVID-19 related Obstetric Anaesthesia Longitudinal Assessment-Registry) wurden sowohl von M{\"a}rz bis Mai 2020 als auch von Oktober 2020 bis Februar 2021 in Deutschland und der Schweiz w{\"o}chentlich prospektiv Daten zu Verdachts- und best{\"a}tigten SARS-CoV-2-F{\"a}llen bei Schwangeren zum Zeitpunkt der Geburt erhoben. Betrachtet wurden die Verteilung dieser auf die Anzahl der Geburten, Zentren und Erhebungswochen sowie m{\"u}tterliche Charakteristika und Krankheitsverl{\"a}ufe. Ergebnisse Neun Zentren haben im Verlauf 44 SARS-CoV-2-positive Schwangere zum Zeitpunkt der Geburt bei 7167 Geburten (0,6 \%) gemeldet (3 F{\"a}lle auf 2270 Geburten (0,4 \%) und 41 F{\"a}lle auf 4897 Geburten (0,8 \%)). Berichtet wurden 2 schwere COVID-19-Verl{\"a}ufe (n = 1 mit Todesfolge nach ECMO, n = 1 mit ECMO {\"u}berlebt). Bei 28 (68 \%) Patientinnen verlief die Infektion asymptomatisch. Ein Neugeborenes wurde im Verlauf positiv auf SARS-CoV‑2 getestet. Schlussfolgerung Mithilfe des Registers konnte das Auftreten von F{\"a}llen zu Beginn der Pandemie zeitnah eingesch{\"a}tzt werden. Es traten sporadisch Verdachtsf{\"a}lle bzw. best{\"a}tigte F{\"a}lle auf. Aufgrund fehlender fl{\"a}chendeckender Testung muss aber von einer Dunkelziffer asymptomatischer F{\"a}lle ausgegangen werden. W{\"a}hrend der zweiten Infektionswelle wurden 68 \% asymptomatische F{\"a}lle gemeldet. Jedoch kann es bei jungen, gesunden Patientinnen ohne das Vorliegen typischer Risikofaktoren zu schwerwiegenden Verl{\"a}ufen kommen.},
  language  = {de}
}
@article{KieselBeyersKaliszetal.2022,
  author    = {Kiesel, Matthias and Beyers, Inga and Kalisz, Adam and W{\"o}ckel, Achim and Herbert, Saskia-Laureen and Curtaz, Carolin and Diessner, Joachim and Joukhadar, Ralf and Wulff, Christine},
  title     = {Introducing a novel model for simulating large loop excision of the transformation zone (LLETZ) using 3D printing technique},
  series = {Archives of Gynecology and Obstetrics},
  volume    = {305},
  journal   = {Archives of Gynecology and Obstetrics},
  number    = {3},
  issn      = {1432-0711},
  doi       = {10.1007/s00404-021-06209-1},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-266739},
  pages     = {703-712},
  year      = {2022},
  abstract  = {Purpose Electrosurgery is the gold-standard procedure for the treatment of cervical dysplasia. The quality of the outcome depends on the accuracy of performance, which underlines the role of adequate training of surgeons, especially, as this procedure is often performed by novice surgeons. According to our knowledge, medical simulation has up until now lacked a model, which focuses on realistically simulating the treatment of cervical dysplasia with the concerning anatomy. Methods and Result In our work, we present a model created using 3D printing for holistically simulating diagnostic, as well as surgical interventions of the cervix, as realistically as possible. Conclusion This novel simulator is compared to an existing model and both are evaluated. By doing so, we aim to provide novice gynecologists with standardized and high-quality simulation models for practicing to improve their proficiency.},
  language  = {en}
}
@article{BartmannFischerHuebneretal.2021,
  author    = {Bartmann, Catharina and Fischer, Leah-Maria and H{\"u}bner, Theresa and M{\"u}ller-Reiter, Max and W{\"o}ckel, Achim and McNeill, Rhiannon V. and Schlaiss, Tanja and Kittel-Schneider, Sarah and K{\"a}mmerer, Ulrike and Diessner, Joachim},
  title     = {The effects of the COVID-19 pandemic on psychological stress in breast cancer patients},
  series = {BMC Cancer},
  volume    = {21},
  journal   = {BMC Cancer},
  doi       = {10.1186/s12885-021-09012-y},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-265802},
  year      = {2021},
  abstract  = {Background: The majority of breast cancer patients are severely psychologically affected by breast cancer diagnosis and subsequent therapeutic procedures. The COVID-19 pandemic and associated restrictions on public life have additionally caused significant psychological distress for much of the population. It is therefore plausible that breast cancer patients might be particularly susceptible to the additional psychological stress caused by the pandemic, increasing suffering. In this study we therefore aimed to assess the level of psychological distress currently experienced by a defined group of breast cancer patients in our breast cancer centre, compared to distress levels preCOVID-19 pandemic. Methods: Female breast cancer patients of all ages receiving either adjuvant, neoadjuvant, or palliative therapies were recruited for the study. All patients were screened for current or previous COVID-19 infection. The participants completed a self-designed COVID-19 pandemic questionnaire, the Stress and Coping Inventory (SCI), the National Comprehensive Cancer Network (R) (NCCN (R)) Distress Thermometer (DT), the European Organization for Research and Treatment of Cancer (EORTC) QLQ C30, and the BR23. Results: Eighty-two breast cancer patients were included. Therapy status and social demographic factors did not have a significant effect on the distress caused by the COVID-19 pandemic. The results of the DT pre and during COVID-19 pandemic did not differ significantly. Using the self-designed COVID-19 pandemic questionnaire, we detected three distinct subgroups demonstrating different levels of concerns in relation to SARS-CoV-2. The subgroup with the highest levels of concern reported significantly decreased life quality, related parameters and symptoms. Conclusions: This monocentric study demonstrated that the COVID-19 pandemic significantly affected psychological health in a subpopulation of breast cancer patients. The application of a self-created "COVID-19 pandemic questionnaire"could potentially be used to help identify breast cancer patients who are susceptible to increased psychological distress due to the COVID-19 pandemic, and therefore may need additional intensive psychological support.},
  language  = {en}
}
@article{HarterHaukeHeitzetal.2017,
  author    = {Harter, Philipp and Hauke, Jan and Heitz, Florian and Reuss, Alexander and Kommoss, Stefan and Marm{\´e}, Frederik and Heimbach, Andr{\´e} and Prieske, Katharina and Richters, Lisa and Burges, Alexander and Neidhardt, Guido and de Gregorio, Nikolaus and El-Balat, Ahmed and Hilpert, Felix and Meier, Werner and Kimmig, Rainer and Kast, Karin and Sehouli, Jalid and Baumann, Klaus and Jackisch, Christian and Park-Simon, Tjoung-Won and Hanker, Lars and Kr{\"o}ber, Sandra and Pfisterer, Jacobus and Gevensleben, Heidrun and Schnelzer, Andreas and Dietrich, Dimo and Neunh{\"o}ffer, Tanja and Krockenberger, Mathias and Brucker, Sara Y. and N{\"u}rnberg, Peter and Thiele, Holger and Altm{\"u}ller, Janine and Lamla, Josefin and Elser, Gabriele and du Bois, Andreas and Hahnen, Eric and Schmutzler, Rita},
  title     = {Prevalence of deleterious germline variants in risk genes including \(BRCA1/2\) in consecutive ovarian cancer patients (AGO-TR-1)},
  series = {PLoS ONE},
  volume    = {12},
  journal   = {PLoS ONE},
  number    = {10},
  doi       = {10.1371/journal.pone.0186043},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-173553},
  year      = {2017},
  abstract  = {Background Identification of families at risk for ovarian cancer offers the opportunity to consider prophylactic surgery thus reducing ovarian cancer mortality. So far, identification of potentially affected families in Germany was solely performed via family history and numbers of affected family members with breast or ovarian cancer. However, neither the prevalence of deleterious variants in \(BRCA1/2\) in ovarian cancer in Germany nor the reliability of family history as trigger for genetic counselling has ever been evaluated. Methods Prospective counseling and germline testing of consecutive patients with primary diagnosis or with platinum-sensitive relapse of an invasive epithelial ovarian cancer. Testing included 25 candidate and established risk genes. Among these 25 genes, 16 genes (\(ATM\), \(BRCA1\), \(BRCA2\), \(CDH1\), \(CHEK2\), \(MLH1\), \(MSH2\), \(MSH6\), \(NBN\), \(PMS2\), \(PTEN\), \(PALB2\), \(RAD51C\), \(RAD51D\), \(STK11\), \(TP53\)) were defined as established cancer risk genes. A positive family history was defined as at least one relative with breast cancer or ovarian cancer or breast cancer in personal history. Results In total, we analyzed 523 patients: 281 patients with primary diagnosis of ovarian cancer and 242 patients with relapsed disease. Median age at primary diagnosis was 58 years (range 16-93) and 406 patients (77.6\%) had a high-grade serous ovarian cancer. In total, 27.9\% of the patients showed at least one deleterious variant in all 25 investigated genes and 26.4\% in the defined 16 risk genes. Deleterious variants were most prevalent in the \(BRCA1\) (15.5\%), \(BRCA2\) (5.5\%), \(RAD51C\) (2.5\%) and \(PALB2\) (1.1\%) genes. The prevalence of deleterious variants did not differ significantly between patients at primary diagnosis and relapse. The prevalence of deleterious variants in \(BRCA1/2\) (and in all 16 risk genes) in patients <60 years was 30.2\% (33.2\%) versus 10.6\% (18.9\%) in patients \(\geq\)60 years. Family history was positive in 43\% of all patients. Patients with a positive family history had a prevalence of deleterious variants of 31.6\% (36.0\%) versus 11.4\% (17.6\%) and histologic subtype of high grade serous ovarian cancer versus other showed a prevalence of deleterious variants of 23.2\% (29.1\%) and 10.2\% (14.8\%), respectively. Testing only for \(BRCA1/2\) would miss in our series more than 5\% of the patients with a deleterious variant in established risk genes. Conclusions 26.4\% of all patients harbor at least one deleterious variant in established risk genes. The threshold of 10\% mutation rate which is accepted for reimbursement by health care providers in Germany was observed in all subgroups analyzed and neither age at primary diagnosis nor histo-type or family history sufficiently enough could identify a subgroup not eligible for genetic counselling and testing. Genetic testing should therefore be offered to every patient with invasive epithelial ovarian cancer and limiting testing to \(BRCA1/2\) seems to be not sufficient.},
  language  = {en}
}
@article{AbuHalimaHaeuslerBackesetal.2017,
  author    = {Abu-Halima, Masood and H{\"a}usler, Sebastian and Backes, Christina and Fehlmann, Tobias and Staib, Claudia and Nestel, Sigrun and Nazarenko, Irina and Meese, Eckart and Keller, Andreas},
  title     = {Micro-ribonucleic acids and extracellular vesicles repertoire in the spent culture media is altered in women undergoing \(In\) \(Vitro\) Fertilization},
  series = {Scientific Reports},
  volume    = {7},
  journal   = {Scientific Reports},
  doi       = {10.1038/s41598-017-13683-8},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-173632},
  year      = {2017},
  abstract  = {MicroRNAs (miRNAs) are class of small RNA molecules with major impact on gene regulation. We analyzed the potential of miRNAs secreted from pre-implantation embryos into the embryonic culture media as biomarkers to predict successful pregnancy. Using microarray analysis, we profiled the miRNome of the 56 spent culture media (SCM) after embryos transfer and found a total of 621 miRNAs in the SCM. On average, we detected 163 miRNAs in SCM of samples with failed pregnancies, but only 149 SCM miRNAs of embryos leading to pregnancies. MiR-634 predicted an embryo transfer leading to a positive pregnancy with an accuracy of 71\% and a sensitivity of 85\%. Among the 621 miRNAs, 102 (16.4\%) showed a differential expression between positive and negative outcome of pregnancy with miR-29c-3p as the most significantly differentially expressed miRNA. The number of extracellular vehicles was lower in SCM with positive outcomes (3.8 × 10\(^9\)/mL EVs), as compared to a negative outcome (7.35 × 10\(^9\)/mL EVs) possibly explaining the reduced number of miRNAs in the SCM associated with failed pregnancies. The analysis of the miRNome in the SCM of couples undergoing fertility treatment lays the ground towards development of biomarkers to predict successful pregnancy and towards understanding the role of embryonic miRNAs found in the SCM.},
  language  = {en}
}
@article{GernertKieselFroehlichetal.2021,
  author    = {Gernert, Michael and Kiesel, Matthias and Fr{\"o}hlich, Matthias and Renner, Regina and Strunz, Patrick-Pascal and Portegys, Jan and Tony, Hans-Peter and Schmalzing, Marc and Schwaneck, Eva Christina},
  title     = {High Prevalence of Genital Human Papillomavirus Infection in Patients With Primary Immunodeficiencies},
  series = {Frontiers in Immunology},
  volume    = {12},
  journal   = {Frontiers in Immunology},
  issn      = {1664-3224},
  doi       = {10.3389/fimmu.2021.789345},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-250273},
  year      = {2021},
  abstract  = {Background Genital human papillomavirus (HPV)-infections are common in the general population and are responsible for relevant numbers of epithelial malignancies. Much data on the HPV-prevalence is available for secondary immunodeficiencies, especially for patients with human immunodeficiency virus (HIV)-infection. Little is known about the genital HPV-prevalence in patients with primary immunodeficiencies (PIDs). Methods We performed a cross-sectional study of patients with PIDs and took genital swabs from male and female patients, which were analyzed with polymerase chain reaction for the presence of HPV-DNA. Clinical and laboratory data was collected to identify risk factors. Results 28 PID patients were included in this study. 10 of 28 (35.7\%) had HPV-DNA in their genital swabs. 6 patients had high-risk HPV-types (21.4\%). Most patients had asymptomatic HPV-infections, as genital warts were rare (2 of 28 patients) and HPV-associated malignancy was absent. Differences in the HPV-positivity regarding clinical PID-diagnosis, duration of PID, age, sex, immunosuppression, immunoglobulin replacement, or circumcision in males were not present. HPV-positive PID patients had higher numbers of T cells (CD3\(^+\)), of cytotoxic T cells (CD3\(^+\)/CD8\(^+\)), of transitional B cells (CD19\(^+\)/CD38\(^{++}\)/CD10\(^+\)/IgD\(^+\)), and of plasmablasts (CD19\(^+\)/CD38\(^+\)/CD27\(^{++}\)/IgD\(^-\)) compared to HPV-negative. Conclusion PID patients exhibit a high rate of genital HPV-infections with a high rate of high-risk HPV-types. Regular screening for symptomatic genital HPV-infection and HPV-associated malignancy in PID patients seems recommendable.},
  language  = {en}
}
@article{StanglRauchRauhetal.2021,
  author    = {Stangl, Stephanie and Rauch, Sebastian and Rauh, J{\"u}rgen and Meyer, Martin and M{\"u}ller-Nordhorn, Jacqueline and Wildner, Manfred and W{\"o}ckel, Achim and Heuschmann, Peter U.},
  title     = {Disparities in Accessibility to Evidence-Based Breast Cancer Care Facilities by Rural and Urban Areas in Bavaria, Germany},
  series = {Cancer},
  volume    = {127},
  journal   = {Cancer},
  number    = {13},
  doi       = {10.1002/cncr.33493},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-239854},
  pages     = {2319 -- 2332},
  year      = {2021},
  abstract  = {Background Breast cancer (BC), which is most common in elderly women, requires a multidisciplinary and continuous approach to care. With demographic changes, the number of patients with chronic diseases such as BC will increase. This trend will especially hit rural areas, where the majority of the elderly live, in terms of comprehensive health care. Methods Accessibility to several cancer facilities in Bavaria, Germany, was analyzed with a geographic information system. Facilities were identified from the national BC guideline and from 31 participants in a proof-of-concept study from the Breast Cancer Care for Patients With Metastatic Disease registry. The timeframe for accessibility was defined as 30 or 60 minutes for all population points. The collection of address information was performed with different sources (eg, a physician registry). Routine data from the German Census 2011 and the population-based Cancer Registry of Bavaria were linked at the district level. Results Females from urban areas (n = 2,938,991 [ie, total of females living in urban areas]) had a higher chance for predefined accessibility to the majority of analyzed facilities in comparison with females from rural areas (n = 3,385,813 [ie, total number of females living in rural areas]) with an odds ratio (OR) of 9.0 for cancer information counselling, an OR of 17.2 for a university hospital, and an OR of 7.2 for a psycho-oncologist. For (inpatient) rehabilitation centers (OR, 0.2) and genetic counselling (OR, 0.3), women from urban areas had lower odds of accessibility within 30 or 60 minutes. Conclusions Disparities in accessibility between rural and urban areas exist in Bavaria. The identification of underserved areas can help to inform policymakers about disparities in comprehensive health care. Future strategies are needed to deliver high-quality health care to all inhabitants, regardless of residence.},
  language  = {en}
}